Europe's drugmakers pushed for a decision as early as June on the new location for the headquarters of the bloc's medicines watchdog, which will relocate from London after Britain's decision to leave the EU. The new location will be decided by the EU's heads of state, whose next meeting as the European Council is scheduled for June 22-23. "The Council's deliberations on the Agency's future location need to be conducted on the basis of very essential criteria and put for decision as early on as possible, preferably at its meeting in June this year," European pharma lobby group EFPIA said in a statement on Monday signed by 19 top executives at member companies including Pfizer, Novartis, Sanofi and Roche.
- Motley Fool•5 days ago
The drugmaker reported that veliparib failed to outperform standard treatment in breast cancer and non-small-cell lung cancer trials.
- American City Business Journals•5 days ago
As part of a two-day BioHealth Capital Regional Forum that began Wednesday at MedImmune headquarters, the research and development arm of London-based AstraZeneca PLC (AZN), organizers announced a new website to serve as a single place to tell the world about the region's biotech offerings, from Inova Health System's Center for Personalized Health campus in Merrifield to Johns Hopkins University's new business incubator in Baltimore. “If you ask a lot of the outside world today about the region, they’ll think of bureaucracy, they’ll think of inefficiency,” said Jarrod Borkat, MedImmune’s senior director of global academic, government and foundation collaborations.
AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||4,701.00 x 6100|
|Ask||4,702.00 x 13000|
|Day's Range||4,634.00 - 4,765.62|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||17.04|
|Dividend & Yield||2.80 (4.81%)|
|1y Target Est||N/A|